Welcome to CDC stacks | Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors - 57804 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors
  • Published Date:
    Mar 24 2018
  • Source:
    Haemophilia. 24(3):e116-e119.
  • Language:
    English
Filetype[PDF-141.16 KB]


No Related Documents.
You May Also Like:
  1. Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review
    Personal Author:
    Miller, C. H.
    Published:
    Feb 15 2018
    Source:
    Haemophilia. 24(2):186-197.
    Description:
    Inhibitors are antibodies directed against haemophilia treatment products which interfere with their function. Factor VIII (FVIII) inhibitors in haemophilia A and factor IX (FIX) inhibitors in haemophilia B are significant clinically when they requir...
    File Type:
    Filetype[PDF - 690.23 KB]
  2. Improving the performance of factor VIII inhibitor tests in hemophilia A
    Personal Author:
    Miller, Connie H.
    Published:
    Sep 28 2015
    Source:
    Thromb Res. 136(6):1047-1048.
    File Type:
    Filetype[PDF - 41.93 KB]
  3. Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inhibitor Surveillance
    Personal Author:
    Miller, C. H.; Platt, S. J.; Rice, A. S.; Kelly, F.; Soucie, J. M.;
    Corporate Author:
    Hemophilia Inhibitor Research Study Investigators
    Published:
    Jun 2012
    Source:
    J Thromb Haemost. 10(6):1055-1061.
    Description:
    Background : As part of a pilot U.S. inhibitor surveillance project initiated at the Centers for Disease Control and Prevention (CDC) in 2006, centralized inhibitor measurement was instituted. : Objective : To validate a modified method for inhibitor...
    File Type:
    Filetype[PDF - 1.03 MB]
  4. Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors
    Personal Author:
    Miller, Connie H.; Boylan, Brian; Shapiro, Amy D.; Lentz, Steven R.; Wicklund, Brian M.;
    Published:
    Sep 14 2017
    Source:
    J Thromb Haemost. 15(10):1971-1976.
    Description:
    Background : The Bethesda assay (BA) for measurement of factor VIII (FVIII) inhibitors called for quantitation of positive inhibitors using dilutions producing 25–75% residual activity (RA), corresponding to 0.4–2.0 Bethesda units, recommending u...
    File Type:
    Filetype[PDF - 332.11 KB]
  5. Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study
    Personal Author:
    Miller, Connie H.; Rice, Anne S.; Boylan, Brian; Shapiro, Amy D.; Lentz, Steven R.; Wicklund, Brian M.; Kelly, Fiona M.; Soucie, J. Michael;
    Corporate Author:
    Hemophilia Inhibitor Research Study Investigators
    Published:
    Jul 2013
    Source:
    J Thromb Haemost. 11(7):1300-1309.
    Description:
    Background : Detection and validation of inhibitors (antibodies) to hemophilia treatment products are important for clinical care, evaluation of product safety, and assessment of population trends. : Methods : Centralized monitoring for factor VIII (...
    File Type:
    Filetype[PDF - 849.05 KB]